US-based iCeutica announced that its partner Iroko Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to market ZORVOLEX (diclofenac) capsules, a non-steroidal anti-inflammatory drug (NSAID) that utilizes SoluMatrix Fine Particle Technology.
Iroko developed ZORVOLEX capsules under a collaboration and license agreement with iCeutica.
This is one of several products in development by Iroko that utilize iCeutica's SoluMatrix Fine Particle Technology.
iCeutica president and CEO Matthew Callahan added the team is excited by the validation that this regulatory approval brings to its approach to creating new branded medicines with SoluMatrix technology.
"The royalty revenue we will receive from the sales of ZORVOLEX (diclofenac) capsules will help us continue to advance our internal product candidates in therapeutic areas such as oncology and respiratory disease.
"We congratulate our partner, Iroko, on this important milestone and we look forward to the progression of additional products iCeutica is developing in collaboration with Iroko as they move towards regulatory approval," Callahan added.
iCeutica creates branded medicines that provide meaningful clinical benefits to patients, physicians and payers and is developing a pipeline of products that utilize SoluMatrix Fine Particle Technology. iCeutica commercializes those products with partners and through establishing new companies in focused therapeutic areas.